病学的观点:个性化管理IgA病,超越KDIGO
Hernán Trimarchi1, Fernando C Fervenza2, Rosanna Coppo3
1Nephrology Service, Hospital Británico de Buenos Aires, Buenos Aires, Argentina.
Journal of nephrology
|January 18, 2024
概括
作为衰竭的常见原因,IgA病需要个性化治疗,超出目前的指导方针. 案例研究强调,需要考虑临床,组织学和社会因素,以获得最佳的患者护理.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
背景情况:
- 在全球范围内,IgA脏病是最常见的原发性淋巴细胞突炎,导致20%-40%的患者功能衰竭.
- 临床表现有很大的不同,从微观的血到脏综合征和快速进展.
- 种族和表观遗传学等因素影响疾病的严重程度,使治疗决策复杂化.
研究的目的:
- 为了说明管理IgA病的挑战.
- 强调需要个性化的治疗方法,超出目前的指导方针.
- 介绍来自不同国家的IgA病的不同临床病例.
主要方法:
- 审查来自不同国际环境的三起IgA病例.
- 分析患者管理中的临床,组织学,实验室,社会和伦理因素.
- 案件管理与现有的KDIGO 2021指南的比较.
主要成果:
- 目前的指导方针侧重于蛋白尿 >1g/24h,可能无法满足所有患者的需求.
- 脏活检结果 (牛津分类) 提供预后价值,但并不总是足够的.
- 考虑到患者多面性特征的个性化治疗至关重要.
结论:
- 针对性治疗对于具有独特特征的IgA病患者来说至关重要.
- 临床实践需要整合各种方面,以有效管理IgA病.
- 对IgA病的个性化治疗策略进行进一步的研究是有必要的.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Chronic Pancreatitis II: Collaborative Care
92
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
92
Gastritis III: Clinical Manifestations and Management
263
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
263
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432


